HTR2A and metabolic dysfunction-associated steatotic liver disease: In addition, as the mortality increases geometrically with the increasing levels of fibrosis in NAFLD patients and many of genes involved in proinflammatory and profibrogenic pathways are downregulated in Htr2a LKO mice, it would be of interest to test whether HTR2A antagonism can effectively stop the progression of hepatic steatosis to fibrosis in the future45.